EGFR TK inhibitors approved for the treatment of advanced NSCLC include afatinib, dacomitinib, erlotinib, gefitinib, almonertinib, brigatinib, icotinib, olmutinib, and osimertinib [13,14]. Here, TKT is linked to non-small cell lung carcinoma.